• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Universe Pharmaceuticals INC Receives Staff Determination Notice from Nasdaq Related to Delayed Annual Report

    2/25/25 4:10:00 PM ET
    $UPC
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $UPC alert in real time by email

    Ji'an, Jiangxi, China, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the "Company") (NASDAQ:UPC), a pharmaceutical producer and distributor in China, today announced that on February 19, 2025, the Company received a staff determination notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that it is delinquent in filing its Annual Report on Form 20-F for the fiscal year ended September 30, 2024 (the "Form 20-F") and that this matter serves as an additional basis for delisting the Company's securities from Nasdaq. The failure to timely file the Form 20-F is a violation of Nasdaq Listing Rule 5250(c)(1).

    The Company is before a Hearings Panel for its failure to comply with Listing Rule 5550(a)(2) and was therefore provided until February 26, 2025 to request a stay of the suspension of the Company's securities, pending a Hearings Panel decision. The Company intends to request a stay of the suspension before that date. The Company is working on completing and filing the delayed Form 20-F.

    This announcement is being made in compliance with Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification.

    About Universe Pharmaceuticals INC

    Universe Pharmaceuticals INC, headquartered in Ji'an, Jiangxi, China, is a pharmaceutical producer and distributor in China. The Company specializes in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the aging process and to promote their general well-being. The Company also distributes and sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Currently, the Company's products are sold in 30 provinces of China. For more information, visit the company's website at http://www.universe-pharmacy.com/.

    Forward-Looking Statements

    All statements other than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and in its other filings with the U.S. Securities and Exchange Commission.

    Contact:

    Ms. Lin Yang,

    Chief Financial Officer of Universe Pharmaceuticals INC

    [email protected]



    Primary Logo

    Get the next $UPC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $UPC

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $UPC
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13G/A filed by Universe Pharmaceuticals Inc.

      SCHEDULE 13G/A - Universe Pharmaceuticals INC (0001809616) (Subject)

      5/15/25 6:07:40 PM ET
      $UPC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 20-F filed by Universe Pharmaceuticals Inc.

      20-F - Universe Pharmaceuticals INC (0001809616) (Filer)

      4/29/25 4:05:32 PM ET
      $UPC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 6-K filed by Universe Pharmaceuticals Inc.

      6-K - Universe Pharmaceuticals INC (0001809616) (Filer)

      3/20/25 8:33:28 AM ET
      $UPC
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $UPC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $UPC
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $UPC
    Leadership Updates

    Live Leadership Updates

    See more
    • SEC Form SC 13G/A filed by Universe Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Universe Pharmaceuticals INC (0001809616) (Subject)

      2/14/23 2:14:41 PM ET
      $UPC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Universe Pharmaceuticals Inc.

      SC 13G - Universe Pharmaceuticals INC (0001809616) (Subject)

      2/11/22 8:00:43 AM ET
      $UPC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Universe Pharmaceuticals Inc.

      SC 13G - Universe Pharmaceuticals INC (0001809616) (Subject)

      12/28/21 4:10:53 PM ET
      $UPC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Universe Pharmaceuticals INC Announces Share Consolidation

      Jiangxi, China, March 20, 2025 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (NASDAQ:UPC) ("Universe Pharmaceuticals" or the "Company"), a pharmaceutical producer and distributor in China, today announced that the Company plans to effect a share consolidation of 40 ordinary shares with par value of US$0.28125 per share each in the Company's issued and unissued share capital into one (1) ordinary share with par value of US$11.25 (the "Share Consolidation"). As a result of the Share Consolidation, each 40 pre-consolidation ordinary shares outstanding will automatically combine and convert to one issued and outstanding ordinary share without any action on the part of the shareholders. Th

      3/20/25 8:30:00 AM ET
      $UPC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Universe Pharmaceuticals INC Receives Staff Determination Notice from Nasdaq Related to Delayed Annual Report

      Ji'an, Jiangxi, China, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the "Company") (NASDAQ:UPC), a pharmaceutical producer and distributor in China, today announced that on February 19, 2025, the Company received a staff determination notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq"), notifying the Company that it is delinquent in filing its Annual Report on Form 20-F for the fiscal year ended September 30, 2024 (the "Form 20-F") and that this matter serves as an additional basis for delisting the Company's securities from Nasdaq. The failure to timely file the Form 20-F is a violation of Nasdaq Listing Rule 5250(c)(1). The Com

      2/25/25 4:10:00 PM ET
      $UPC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Universe Pharmaceuticals INC Receives Nasdaq Delisting Notice Subject to Hearing Request

      Ji'an, Jiangxi, China, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the "Company") (NASDAQ:UPC), a pharmaceutical producer and distributor in China, today announced that the Company received a letter from the Nasdaq Stock Market LLC ("Nasdaq") on January 29, 2025, notifying the Company that the Nasdaq staff has determined to delist the Company's ordinary shares from The Nasdaq Capital Market (the "Delisting Determination"), because the bid price of the Company's listed securities has closed at less than $1 per share over the previous 30 consecutive business days, and therefore no longer complies with the Nasdaq Listing Rule 5550(a)(2) (the "Rule"). Normally, a company w

      2/3/25 4:10:00 PM ET
      $UPC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Universe Pharmaceuticals INC Appoints Mr. Baochang Liu as Chief Operating Officer

      Ji'an, Jiangxi, China, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Universe Pharmaceuticals INC (the "Company") (NASDAQ:UPC), a pharmaceutical producer and distributor in China, today announced that the Company appointed Mr. Baochang Liu as its Chief Operating Officer, effective December 1, 2021. Mr. Baochang Liu has over 17 years of experience in pharmaceutical marketing. Mr. Baochang Liu has been working as the vice president of marketing and general manager of OTC department at China Shineway Pharmaceutical Group Ltd. since December 2019. Mr. Baochang Liu served as the general manager of OTC department at Chengdu Kanghong Pharmaceutical Group Co., Ltd. from November 2015 to December 2019. Prior

      12/15/21 4:30:00 PM ET
      $UPC
      Biotechnology: Pharmaceutical Preparations
      Health Care